Los Angeles Capital Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.48M Sell
35,358
-169,782
-83% -$31.3M 0.03% 299
2025
Q4
$30.7M Buy
205,140
+13,776
+7% +$2.25M 0.1% 140
2025
Q3
$26.8M Buy
191,364
+147,006
+331% +$19.9M 0.09% 162
2025
Q2
$5.57M Buy
44,358
+1,048
+2% +$131K 0.02% 297
2025
Q1
$5.93M Buy
+43,310
New +$6.19M 0.03% 262
2024
Q4
Sell
-4,282
Closed -$830K 1123
2024
Q3
$830K Buy
+4,282
New +$896K ﹤0.01% 706
2023
Q3
Sell
-1,014
Closed -$289K 1124
2023
Q2
$289K Sell
1,014
-60,617
-98% -$18M ﹤0.01% 1013
2023
Q1
$17.1M Sell
61,631
-139,445
-69% -$38.6M 0.08% 217
2022
Q4
$55.7M Buy
201,076
+48,908
+32% +$13.8M 0.27% 92
2022
Q3
$40.6M Buy
152,168
+111,159
+271% +$23.6M 0.21% 112
2022
Q2
$8.36M Buy
41,009
+26,464
+182% +$5.41M 0.04% 296
2022
Q1
$3.06M Buy
14,545
+9,490
+188% +$2.06M 0.01% 443
2021
Q4
$1.21M Buy
5,055
+2,782
+122% +$715K ﹤0.01% 656
2021
Q3
$643K Sell
2,273
-1,820
-44% -$597K ﹤0.01% 945
2021
Q2
$1.42M Sell
4,093
-37,107
-90% -$11.2M 0.01% 705
2021
Q1
$11.5M Sell
41,200
-10,679
-21% -$2.88M 0.05% 285
2020
Q4
$12.7M Sell
51,879
-195,234
-79% -$50.4M 0.05% 242
2020
Q3
$70.1M Sell
247,113
-6,920
-3% -$1.93M 0.32% 68
2020
Q2
$68M Buy
254,033
+17,166
+7% +$5.16M 0.33% 75
2020
Q1
$74.9M Sell
236,867
-163,714
-41% -$49.7M 0.47% 54
2019
Q4
$119M Buy
400,581
+292,927
+272% +$81.3M 0.59% 33
2019
Q3
$25.1M Buy
107,654
+13,831
+15% +$3.22M 0.14% 158
2019
Q2
$21.9M Buy
93,823
+22,505
+32% +$5.2M 0.12% 195
2019
Q1
$16.9M Buy
71,318
+19,834
+39% +$6.25M 0.09% 226
2018
Q4
$15.5M Buy
51,484
+61
+0.1% +$19.5K 0.1% 214
2018
Q3
$18.2M Sell
51,423
-131,733
-72% -$45.4M 0.1% 232
2018
Q2
$53.2M Sell
183,156
-114,664
-39% -$32.2M 0.29% 71
2018
Q1
$81.5M Buy
297,820
+37,730
+15% +$11.7M 0.46% 42
2017
Q4
$82.9M Buy
260,090
+104,237
+67% +$33.4M 0.45% 45
2017
Q3
$48.8M Buy
155,853
+13,422
+9% +$3.97M 0.28% 93
2017
Q2
$38.6M Sell
142,431
-145,274
-50% -$38.4M 0.24% 106
2017
Q1
$78.7M Buy
287,705
+265,851
+1,216% +$75.2M 0.57% 32
2016
Q4
$6.2M Buy
21,854
+9,859
+82% +$2.92M 0.05% 367
2016
Q3
$3.75M Buy
11,995
+5,450
+83% +$1.61M 0.03% 465
2016
Q2
$1.58M Buy
6,545
+2,636
+67% +$695K 0.01% 586
2016
Q1
$1.02M Buy
3,909
+338
+9% +$89.3K 0.01% 619
2015
Q4
$1.09M Buy
3,571
+10
+0.3% +$2.87K 0.01% 652
2015
Q3
$1.04M Sell
3,561
-89,466
-96% -$29.5M 0.01% 692
2015
Q2
$37.6M Sell
93,027
-45,881
-33% -$18.4M 0.35% 82
2015
Q1
$58.7M Sell
138,908
-15,801
-10% -$6.23M 0.54% 37
2014
Q4
$52.5M Buy
154,709
+87,540
+130% +$28.3M 0.48% 50
2014
Q3
$22.2M Sell
67,169
-11,021
-14% -$3.63M 0.27% 106
2014
Q2
$24.7M Sell
78,190
-65,475
-46% -$19.7M 0.24% 126
2014
Q1
$43.9M Buy
143,665
+119,754
+501% +$38M 0.48% 52
2013
Q4
$6.68M Sell
23,911
-19,253
-45% -$4.98M 0.07% 289
2013
Q3
$10.4M Buy
43,164
+16,737
+63% +$3.75M 0.13% 220
2013
Q2
$5.69M Buy
+26,427
New +$5.65M 0.08% 271

Other funds holding BIIB

Los Angeles Capital Management's BIIB Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Biogen (BIIB) stake by 83% in Q1 2026, selling an estimated $31.3M and leaving 35,358 shares worth $6.48M. The position accounts for 0.03% of the portfolio, ranked #299.

Los Angeles Capital Management first reported a position in BIIB in Q2 2013 and has held it in 47 quarters since. The position peaked at $119M in Q4 2019. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Los Angeles Capital Management held 35,358 shares of Biogen worth $6.48M as of Q1 2026.
  • Los Angeles Capital Management sold 169,782 Biogen shares in Q1 2026, an estimated $31.3M.
  • Biogen made up 0.03% of Los Angeles Capital Management's portfolio in Q1 2026, its #299 holding.
  • Los Angeles Capital Management first reported a position in Biogen in Q2 2013 and has held it in 47 quarters since.
  • Los Angeles Capital Management's Biogen position peaked at $119M in Q4 2019.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.